Sinopharm Statistics
Share Statistics
Sinopharm has 629.06M
shares outstanding. The number of shares has increased by null%
in one year.
| Shares Outstanding | 629.06M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 2,905 |
| FTD / Avg. Volume | 14.35% |
Short Selling Information
The latest short interest is 15.41K, so 0% of the outstanding
shares have been sold short.
| Short Interest | 15.41K |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is 8.77 and the forward
PE ratio is null.
Sinopharm's PEG ratio is
-0.4.
| PE Ratio | 8.77 |
| Forward PE | n/a |
| PS Ratio | 0.11 |
| Forward PS | 0 |
| PB Ratio | 0.78 |
| P/FCF Ratio | 6.45 |
| PEG Ratio | -0.4 |
Financial Ratio HistoryEnterprise Valuation
Sinopharm has an Enterprise Value (EV) of 331.16B.
| EV / Sales | 0.57 |
| EV / EBITDA | 15.43 |
| EV / EBIT | 28.68 |
| EV / FCF | 34.58 |
Financial Position
The company has a current ratio of 1.39,
with a Debt / Equity ratio of 0.97.
| Current Ratio | 1.39 |
| Quick Ratio | 1.14 |
| Debt / Equity | 0.97 |
| Debt / EBITDA | 3.56 |
| Debt / FCF | 7.98 |
| Interest Coverage | 5.92 |
Financial Efficiency
Return on Equity is 8.94% and Return on Invested Capital is 5.82%.
| Return on Equity | 8.94% |
| Return on Assets | 1.79% |
| Return on Invested Capital | 5.82% |
| Revenue Per Employee | $5,401,257.94 |
| Profits Per Employee | $65,143.95 |
| Employee Count | 108,217 |
| Asset Turnover | 1.49 |
| Inventory Turnover | 8.66 |
Taxes
| Income Tax | 3.58B |
| Effective Tax Rate | 25.55% |
Stock Price Statistics
The stock price has increased by -11.66% in the
last 52 weeks. The beta is 0.56, so Sinopharm's
price volatility has been higher than the market average.
| Beta | 0.56 |
| 52-Week Price Change | -11.66% |
| 50-Day Moving Average | 11.63 |
| 200-Day Moving Average | 12.47 |
| Relative Strength Index (RSI) | 60.25 |
| Average Volume (20 Days) | 20,246 |
Income Statement
In the last 12 months, Sinopharm had revenue of 584.51B
and earned 7.05B
in profits. Earnings per share was 11.3.
| Revenue | 584.51B |
| Gross Profit | 44.26B |
| Operating Income | 16.19B |
| Net Income | 7.05B |
| EBITDA | 21.47B |
| EBIT | 16.73B |
| Earnings Per Share (EPS) | 11.3 |
Full Income StatementBalance Sheet
The company has 54.31B in cash and 76.39B in
debt, giving a net cash position of -22.07B.
| Cash & Cash Equivalents | 54.31B |
| Total Debt | 76.39B |
| Net Cash | -22.07B |
| Retained Earnings | 53.74B |
| Total Assets | 392.83B |
| Working Capital | 97.07B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was 11.55B
and capital expenditures -1.97B, giving a free cash flow of 9.58B.
| Operating Cash Flow | 11.55B |
| Capital Expenditures | -1.97B |
| Free Cash Flow | 9.58B |
| FCF Per Share | 3.07 |
Full Cash Flow StatementMargins
Gross margin is 7.57%, with operating and profit margins of 2.77% and 1.21%.
| Gross Margin | 7.57% |
| Operating Margin | 2.77% |
| Pretax Margin | 2.4% |
| Profit Margin | 1.21% |
| EBITDA Margin | 3.67% |
| EBIT Margin | 2.77% |
| FCF Margin | 1.64% |
